Study of oral azacytidine plus romidepsin for relapsed T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether an oral drug (azacytidine) plus romidepsin works better than a standard “doctor’s choice” treatment for people with relapsed or refractory peripheral T-cell lymphoma. It’s for adults whose disease has come back or did not respond after prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have peripheral T-cell lymphoma that has come back or is resistant, confirmed by biopsy, and you’ve had 1 prior treatment overall (at least one line of systemic therapy) that stopped working
- You can have had no more than 3 prior treatment lines (and a prior stem cell transplant counts as one line)
- Your lymphoma should be measurable on scans/tests (the study uses specific “measurable disease” rules)
- You are 18 or older, and your overall health/activity level is not too limited (ECOG 0–2)
- Your blood counts and organ tests (kidneys, liver, electrolytes like potassium and magnesium) meet required minimums
- If you have an anaplastic large cell lymphoma type, you must have already received brentuximab vedotin (Bv)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of targeted drugs (including an EZH2 inhibitor) for people with peripheral T-cell lymphoma (PTCL) that didn't respond to their first treatment. The drugs are chosen based on the genetic mutations in your tumor, aiming to attack the cancer more precisely.
This trial tests a new drug called TR115 against the standard treatment options for people with peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if TR115 can help shrink tumors and improve outcomes.
This trial is testing a combination of two drugs for T-cell lymphoma that has returned after prior treatment. The drugs are belinostat (given as an infusion) plus either azacitidine or pralatrexate. The goal is to see if this combination can help control the lymphoma and for how long.
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
Hear when a new PTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.